In short
Eribulin, also known by its brand name Halaven, is a chemotherapy drug being studied in various clinical trials for the treatment of advanced solid tumors and metastatic cancers. These trials aim to evaluate the safety, efficacy, and optimal dosing of eribulin in different patient populations, including those with impaired liver or kidney function. Researchers are exploring eribulin's potential as both a first-line treatment and in patients who have progressed on other therapies.
At a glance
- Drug Name
- Eribulin (also known as E7389, Halaven)
- Type of Drug
- Chemotherapy, microtubule dynamics inhibitor
- Administration
- Intravenous injection, typically on days 1 and 8 of a 21-day cycle
- Cancers Studied
- Advanced solid tumors, metastatic breast cancer, HER2-negative breast cancer
- Key Study Objectives
- Efficacy, safety, pharmacokinetics, optimal dosing
- Special Populations
- Patients with liver impairment, kidney impairment, elderly patients
- Outcome Measures
- Tumor response, time to progression, overall survival, adverse events
- Dosage Range
- 0.7 mg/m² to 1.4 mg/m², adjusted based on organ function and tolerability
What is Eribulin?
Eribulin, also known by its brand names Halaven or E7389, is a chemotherapy medication used primarily in the treatment of certain types of cancer. It belongs to a class of drugs called microtubule inhibitors, which work by interfering with the growth and spread of cancer cells in the body.
What Conditions Does Eribulin Treat?
Eribulin is primarily used to treat:
- Metastatic Breast Cancer: This is breast cancer that has spread to other parts of the body. Eribulin is often used when other treatments have not been effective.
- Advanced Solid Tumors: In some cases, Eribulin may be used to treat other types of advanced or metastatic solid tumors that are no longer responding to available therapies.
How is Eribulin Administered?
Eribulin is typically administered as follows:
- It is given as an intravenous (IV) injection, which means it's delivered directly into your bloodstream through a vein.
- The usual dosing schedule is on days 1 and 8 of a 21-day cycle. This means you receive the medication on the first and eighth day, then have a break for the rest of the three-week period.
- The standard dose is 1.4 mg/m² (milligrams per square meter of body surface area), but this can vary depending on your specific situation.
Side Effects and Safety
Like all medications, Eribulin can cause side effects. Some of the most common ones include:
- Asthenia/Fatigue: Feeling of weakness or lack of energy
- Neutropenia: A decrease in white blood cells, which can increase the risk of infections
- Alopecia: Hair loss
- Nausea: Feeling of sickness in the stomach
- Peripheral Neuropathy: Numbness, tingling, or pain in the hands and feet
- Constipation: Difficulty in bowel movements
Your healthcare team will monitor you closely for these and other potential side effects throughout your treatment.
Special Considerations
There are some special considerations when using Eribulin:
- Liver Function: If you have liver problems, your doctor may adjust your dose of Eribulin. The medication is processed differently in people with mild, moderate, or severe liver impairment.
- Kidney Function: Similarly, if you have kidney problems, your doctor will consider this when determining your Eribulin dose. The medication's behavior in the body can be affected by moderate or severe kidney impairment.
- Pregnancy and Breastfeeding: Eribulin can harm an unborn baby, so it's important to use effective birth control during treatment. It's also not known if Eribulin passes into breast milk, so breastfeeding is not recommended during treatment.
Ongoing Research
Researchers continue to study Eribulin to understand more about its effects and potential uses. Some areas of ongoing research include:
- Combination Therapies: Studies are looking at combining Eribulin with other medications, such as bevacizumab, for treating metastatic breast cancer.
- First-line Treatment: While Eribulin is often used after other treatments have failed, some studies are exploring its use as a first-line treatment for metastatic breast cancer.
- Scalp Cooling: Research is being conducted to see if scalp cooling techniques can help prevent hair loss in patients receiving Eribulin and other chemotherapy drugs.
Remember, while this information provides a general overview, your healthcare team is the best source of information about how Eribulin relates to your specific situation. Always consult with them about any questions or concerns you may have about your treatment.